Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVL-1201 (Upneeq) in acquired blepharoptosis
NCT01848041Phase 2Completed
- Sponsor
- RVL Pharmaceuticals
- Start
- May 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxymetazoline in acquired blepharoptosis, sponsored by RVL Pharmaceuticals. Started May 2013; status: completed.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on NCT01848041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01848041.